Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes

2008 ◽  
Vol 215 (4) ◽  
pp. 377-387 ◽  
Author(s):  
R Fukuzawa ◽  
MR Anaka ◽  
RW Heathcott ◽  
LA McNoe ◽  
IM Morison ◽  
...  
Keyword(s):  
Epigenetic Changes ◽  
Precursor Lesions ◽  
Wilms Tumour ◽  
Tumour Histology

scholarly journals Wilms’ Tumour – Histology and Differential Diagnosis

Wilms Tumor ◽  
2016 ◽  
pp. 3-21 ◽  
Author(s):  
Sergey D. Popov ◽  
◽  
Neil J. Sebire ◽  
Gordan M. Vujanic ◽  
◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Wilms Tumour ◽  
Tumour Histology

Precursor lesions of gastric polyps developing during maintenance omeprazole. A case-control study

2001 ◽  
Vol 120 (5) ◽  
pp. A657-A658
Author(s):  
A CATS ◽  
E BLOEMENA ◽  
E SCHENK ◽  
I CLINICS ◽  
S MEUWISSEN ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
Precursor Lesions ◽  
Gastric Polyps ◽  
Control Study

THE ROLE OF THE GENETIC ABNORMALITIES, EPIGENETIC AND microRNA IN THE PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA

2018 ◽  
Vol 40 (4) ◽  
pp. 261-267 ◽  
Author(s):  
K Tari ◽  
Z Shamsi ◽  
H Reza Ghafari ◽  
A Atashi ◽  
M Shahjahani ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Kinase Inhibitors ◽  
Bone Marrow Involvement ◽  
P53 Mutation ◽  
Lymphocytic Leukemia ◽  
Gene Promoters ◽  
Epigenetic Changes ◽  
Genetic Changes ◽  
Trisomy 12

Chronic lymphocytic leukemia (CLL) is increased proliferation of B-cells with peripheral blood and bone marrow involvement, which is usually observed in older people. Genetic mutations, epigenetic changes and miRs play a role in CLL pathogenesis. Del 11q, del l17q, del 6q, trisomy 12, p53 and IgVH mutations are the most important genetic changes in CLL. Deletion of miR-15a and miR-16a can increase bcl2 gene expression, miR-29 and miR-181 deletions decrease the expression of TCL1, and miR-146a deletion prevents tumor metastasis. Epigenetic changes such as hypo- and hypermethylation, ubiquitination, hypo- and hyperacetylation of gene promoters involved in CLL pathogenesis can also play a role in CLL. Expression of CD38 and ZAP70, presence or absence of mutation in IgVH and P53 mutation are among the factors involved in CLL prognosis. Use of monoclonal antibodies against surface markers of B-cells like anti-CD20 as well as tyrosine kinase inhibitors are the most important therapeutic approaches for CLL.

Sign in / Sign up

Export Citation Format

Share Document